toripalimab   Click here for help

GtoPdb Ligand ID: 12989

Synonyms: JS-001 | JS001 | Loqtorzi® | toripalimab-tpzi
Approved drug Immunopharmacology Ligand
toripalimab is an approved drug (FDA (2023), EMA (2024))
Compound class: Antibody
Comment: Toripalimab (JS001) is an anti-programmed cell death protein-1 (PD-1) immuno-oncology biologic [3]. It blocks the inhibitory immune checkpoint interaction between PD-1 and its ligands and reinstates a cytotoxic T cell response against tumour cells.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Bian L, Zhang H, Wang T, Zhang S, Song H, Xu M, Yao S, Jiang Z. (2019)
JS001, an anti-PD-1 mAb for advanced triple negative breast cancer patients after multi-line systemic therapy in a phase I trial.
Ann Transl Med, 7 (18): 435. [PMID:31700871]
2. Chen SY, Duan XT, Li HF, Peng L, Wang ZQ, Xu GQ, Hua YJ, Zou X, You R, Ouyang YF et al.. (2023)
Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trial.
Cell Rep Med, 4 (11): 101279. [PMID:37951218]
3. Fu J, Wang F, Dong LH, Zhang J, Deng CL, Wang XL, Xie XY, Zhang J, Deng RX, Zhang LB et al.. (2017)
Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
Acta Pharmacol Sin, 38 (5): 710-718. [PMID:28317872]
4. Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi Y, Jin F, Xu R et al.. (2023)
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.
JAMA, 330 (20): 1961-1970. [PMID:38015220]
5. Zheng Y, Liu XB, Sun HB, Xu J, Shen S, Ba YF, Yan M, Qin Z, Liu BX, Wang ZF et al.. (2021)
A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909).
Ann Transl Med, 9 (1): 73. [PMID:33553366]